Form 4 for PHAT Phathom Pharmaceuticals, Inc.

Accepted 2023-07-17 00:00:00 ET · period of report 2023-07-14 · accession 0001209191-23-042453 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-07-17	2023-07-14	PHAT	Nabulsi Azmi	COO	A - Grant	—	+110.0K	209.6K	+110%	—
DM	2023-07-17	2023-07-14	PHAT	Nabulsi Azmi	COO	D - Sale to Iss	—	-220.0K	0	-100%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-07-14	A	A	110,000	—	209,567	D	—	—	(F1) On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.
2	Derivative	Stock Option	2023-07-14	D	D	150,000	—	0	D	$39.11 · — to 2031-01-27	150,000 Common Stock	(F1) On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.
3	Derivative	Stock Option	2023-07-14	D	D	70,000	—	0	D	$32.20 · — to 2030-06-30	70,000 Common Stock	(F1) On July 14, 2023, the Issuer canceled, pursuant to the Issuer's option exchange program, options to purchase 220,000 shares of common stock of the Issuer and in exchange issued to the Reporting Person 110,000 restricted stock units, each of which represents a contingent right to receive one share of the Issuer's common stock.